VVOS

Vivos TherapeuticsB

Nasdaq / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$1.15

+78.8% vs current

Most likely

Base case

45%

Probability

Target price

$0.72

+12.0% vs current

B-

Bear case

30%

Probability

Target price

$0.30

-53.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

This T+3 earnings follow-up did not find a full Q1 2026 earnings release or 10-Q; instead, the key company source was a May 15, 2026 NT 10-Q. That makes the update mixed rather than clearly positive: preliminary operating trends improved, but the reporting delay and expected higher net loss keep confidence capped. Recent coverage is sparse and mostly summary-level, and no trustworthy post-print analyst target or estimate revision set was available, so the stock remains a cautious monitoring situation rather than a clean post-earnings rerating call.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-20catalystDelayed Q1 2026 10-Q is now the nearest proof pointHigh impact

On May 15, 2026 Vivos filed a Form NT 10-Q saying it could not timely file its March 31, 2026 quarter, but it expects to file within the five-day extension period. The notice gave preliminary direction that revenue and gross profit should rise about 70% and 100% year over year, while SG&A should also rise about 70% and net loss should increase because of SCN consolidation and integration. The stock now needs the actual 10-Q to confirm whether gross-profit growth is enough to offset heavier operating costs rather than just headline growth [#NT10Q-2026-05-15].

2026-06-01eventNasdaq equity compliance plan remains a hard deadlineHigh impact

The April 22, 2026 8-K says Nasdaq notified Vivos that its stockholders' equity fell below the $2.5 million minimum, with a compliance plan due by June 1, 2026. Even after first-quarter financings, management said those transactions did not by themselves cure the deficiency, so acceptance of the plan remains a separate listing-status catalyst [#8-K-2026-04-22].

2026-12-31catalystSCN integration must convert revenue growth into lower cash burnHigh impact

Vivos' April 15, 2026 full-year release said 2025 revenue rose 16% and tied the strategic pivot to The Sleep Center of Nevada, while also saying operating loss widened on integration costs and that management is targeting cash-flow-positive operations by year-end. The longer-horizon upside case still depends on proving the provider-centered model can scale with better contribution margins and less financing dependence rather than only faster top-line growth [#PR-2026-04-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology